223. Delay to Diagnosis in Axial Spondyloarthritis: Are we Improving?

Anti-IL17A in Axial Spondyloarthritis—Where Are We At?

Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis (SpA) has been pivotal to the development of IL-17 blockade in patients with axial SpA. Previously, only anti-TNF has proven to be clinically efficacious in patients with active disease, despite non-steroidal anti-inflammatory drugs and physiotherapy. However, up to 50% fail to achieve a clinically sig...

Axial Spondyloarthritis Flares - Whatever They Are.

New developments in the diagnosis and treatment of axial spondyloarthritis

Spondyloarthritis (SpA) is an umbrella term for a group of diseases sharing genetic, molecular, immunological, clinical and imaging features. The last few years have witnessed a remarkable progress in the understanding of SpA. Notable advances include the recognition of MRI as a sensitive and specific tool for detecting axial inflammation and the recent development and validation of the Assessm...

NSAIDs in axial spondyloarthritis: to be continued…?

Phenylbutazone was discovered in 1946 and promptly exhibited efficacy in various rheumatic diseases in the early 1950s. Its efficacy on pain and general well-being was especially present in ankylosing spondylitis (AS), which was then known as ‘rheumatoid spondylitis’. 2 However, even in the early days, non-steroidal antiinflammatory drugs (NSAIDs) were not considered harmless drugs, as the toxi...

Epidemiology of axial spondyloarthritis